Selection of patients for large mailed fecal immunochemical test colorectal cancer screening outreach programs: A systematic review

Abstract

Objective

Digital health care offers an opportunity to scale and personalize cancer screening programs, such as mailed outreach for colorectal cancer (CRC) screening. However, studies that describe the patient selection strategy and process for CRC screening are limited. Our objective was to evaluate implementation strategies for selecting patients for CRC screening programs in large health care systems.

Methods

We conducted a systematic review of 30 studies along with key informant surveys and interviews to describe programmatic implementation strategies for selecting patients for CRC screening. PubMed and Embase were searched since inception through December 2018, and hand searches were performed of the retrieved reference lists but none were incorporated (n = 0). No language exclusions were applied.

Results

Common criteria for outreach exclusion included: being up-to-date with routine CRC screening (n = 22), comorbidities (n = 20), and personal history (n = 22) or family history of cancer (n = 9). Key informant surveys and interviews were performed (n = 28) to understand data sources and practices for patient outreach selection, and found that 13 studies leveraged electronic medical care records, 10 studies leveraged a population registry (national, municipal, community, health), 4 studies required patient opt-in, and 1 study required primary care provider referral. Broad ranges in fecal immunochemical test completion were observed in community clinic (n = 8, 31.0–59.6%), integrated health system (n = 5, 21.2–82.7%), and national regional CRC screening programs (n = 17, 23.0–64.7%). Six studies used technical codes, and four studies required patient self-reporting from a questionnaire to participate.

Conclusion

This systematic review provides health systems with the diverse outreach practices and technical tools to support efforts to automate patient selection for CRC screening outreach.

Keywords

Colon cancer patient selection criteria quality indicators exclusionary factors organized screening

Introduction

Colorectal cancer (CRC) is the second leading cause of cancer deaths in the United States.¹ Despite the increase in CRC screening programs around the world and evidence that the fecal immunochemical test (FIT) is a highly effective and commonly used screening method,² population-level CRC screening could still be greatly improved through increased efforts in population reach, personalization of testing, and integration of interventional research outreach.^3,4

With concerns over screening rates⁵ and the digitization of health records leading to accountable precision population health,⁶ there remain opportunities for large health systems that have not yet established a CRC screening program, and as a checklist for those where CRC screening is already established, to assess the comprehensiveness of their system by responding to standardized quality metrics to improve strategies for CRC screening.⁷

Several clinical trials, systematic reviews, and meta-analyses have identified organized outreach and FIT kit mailing as the most effective strategy.^8–16 However, there is limited data on how patients are selected, including the implementation strategy applied and technical procedural codes used.^17,18 A systematic review evaluating the patient selection process with key informant interviews may help improve organized CRC screening.

Our objective was to evaluate implementation strategies for selecting patients for CRC screening programs in large health care systems. To examine this issue, we performed a systematic review and key informant interviews to describe the factors used to exclude patients from a population-based CRC screening program.

Methods

We performed a systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines.

Data source and literature searches

We developed our search strategy with a medical librarian (EW) using keywords for immunochemical based fecal tests and cancer screening (Supplemental Table 1). We searched PubMed and Embase until 31 December 2018. This systematic review was conducted according to the methods described in the Cochrane Handbook for Systematic Review of Interventions and the PRISMA standard. A review protocol was registered a priori through PROSPERO (CRD42018114370). This study was registered immediately after preliminary searches were conducted but before the main search was conducted.

Table 1.

Characteristics of the included studies performing mailed FIT outreach.

Represented study, year	Study design	Country	Primary health organization	Program type	Number of participants	Type of FIT	Intervention type	Patient identification sources	Up-to-date	Comorbidities	Personal cancer history	Family cancer history	Other	FIT completion	Colonoscopy follow-up
Duncan et al.¹⁹	Nonrandomized	Australia	School of Psychology, The University of Adelaide	National/regional	+	OC-Sensor	Routine + Enhanced Education + Reminder	Clinic		X	X	X		45.8	n/a
Van Roosbroeck et al.²⁰	Nonrandomized	Belgium	Research Group Medical Sociology and Health Policy, Department of Epidemiology and Social Medicine, University of Antwerp	Community clinic	++	OC-Auto	Routine + Enhanced Education + Reminder	Clinic	X	X	X			42.1	72.9
Telford et al.²¹	Nonrandomized	Canada	Department of Medicine (Telford) and School of Population and Public Health (Coldman), University of British Columbia	Community clinic	++	n/a	Routine	n/a	X	X	X			86.0	88.6
Larsen et al.²²	Nonrandomized	Denmark	Department of Public Health Programmes, Randers Regional Hospital	National/regional	+++	n/a	Routine	n/a	X	X	X			67.2	n/a
Sportes et al.²³	Nonrandomized	France	Gastroenterology Unit, Departmental Committee of Cancers-Bondy	National/regional	+++	OC-Sensor	Routine	Population registry		X				30.0	n/a
Pellant et al.²⁴	Nonrandomized	France	Cochin teaching Hospital, Paris Descartes University	National/regional	+++	OC-Sensor	Routine	Population registry	X	X				23.0	70.5
Koivogui et al.²⁵	Nonrandomized	France	Comité Départemental Des Cancers	National/regional	+++	OC-Sensor	Routine	n/a	X	X	X	X		28.4	65.7
Rat et al.²⁶	Randomized	France	Department of General Practice, Faculty of Medicine, Nantes	National/regional	++	n/a	Routine + Enhanced Education + Reminder	n/a	X	X	X	X		24.8	n/a
McNamara et al.²⁷	Nonrandomized	Ireland	Trinity College Dublin	Community clinic	+	OC-Sensor	Routine	Clinic	X					51.0	87
Clarke et al.²⁸	Randomized	Ireland	Department of Epidemiology and Public Health, University College Cork	Community clinic	+	n/a	Enhanced Monitoring + Reminder	n/a			X			59.6	n/a
Rossi²⁹	Nonrandomized	Italy	Inter-institutional Epidemiology Unit, AUSL Reggio Emilia	National/regional	+++	n/a	Routine	n/a			X			64.0	91.7
Grazzini et al.³⁰	Nonrandomized	Italy	ISPO Cancer Prevention and Research Institute Florence	National/regional	++	OC-Hemodial	Routine	Clinic	X	X	X	X		52.3	n/a
Senore et al.³¹	Randomized	Italy	AOU Città della Salute e della Scienza	National/regional	++	n/a	Enhanced Monitoring + Reminder	n/a	X	X	X	X		46.1	n/a
Santare et al.³²	Randomized	Latvia	Institute of Mathematics and Computer Science, University of Latvia	National/regional	++	OC-Sensor	Routine	n/a			X			47.4	n/a
Van Der Vlugt et al.³³	Nonrandomized	Netherlands	Department of Gastroenterology and Hepatology, Academic Medical Centre, University of Amsterdam	National/regional	++	OC-Sensor	Routine + Reminder	n/a	X	X				63.0	n/a
Knudsen et al.³⁴	Nonrandomized	Norway	Department of Bowel cancer screening, Cancer Registry of Norway	National/regional	+	n/a	Routine	n/a	X	X	X			56.7	n/a
Vanaclocha-espi et al.³⁵	Nonrandomized	Spain	Cancer and Public Health Area-FISABIO	National/regional	+++	n/a	Routine + Reminder	Population registry	X				X	48.7	n/a
Guirigu et al.³⁶	Nonrandomized	Spain	Unitat de Suport a la Recerca Metropolitana Nord, Institut Universitari d'Investigació en Atenció Primària Jordi Gol	National/regional	++	n/a	Routine	n/a	X	X		X		48.0	n/a
Binefa et al.³⁷	Nonrandomized	Spain	Cancer Prevention and Control Programme, Instituto Catalán de Oncología, Hospitalet de Llobregat	Community clinic	+++	OC-Sensor	Routine	n/a	X	X	X	X		n/a	94.0
Quintero et al.³⁸	Randomized	Spain	Department of Gastroenterology, Hospital Universitario de Canarias,	National/regional	++	OC-Sensor	Routine	Clinic	X	X	X	X		34.2	86.4
Chen et al.³⁹	Nonrandomized	Taiwan	Digestive Disease Center, Show-Chwan Memorial Hospital	National/regional	+++	OC-Sensor	Routine	n/a			X			n/a	n/a
Vleugels et al.⁴⁰	Nonrandomized	UK	Cancer Screening and Prevention Research Group, Department of Surgery and Cancer, Imperial College London	National/regional	+	OC-Auto	Routine	n/a	X					64.7	97.0
Kemper et al.⁴¹	Nonrandomized	USA	Center for Health Research, Kaiser Permanente Northwest	Community clinic	+	OC-Auto	Enhanced Instructions + Reminder	Clinic	X					31.0	70.0
Ghai et al.¹¹	Nonrandomized	USA	Kaiser Foundation Health Plan, Department of Regional Clinical Effectiveness	Integrated health system	+++	OC-Auto	Routine + Reminder	Health Maintenance Organization		X	X		X	n/a	n/a
Yu et al.⁴²	Nonrandomized	USA	David Geffen School of Medicine	Integrated health system	+	OC-Auto	Routine + Enhanced Monitoring	n/a	X		X		X	21.2	50.8
Corley et al.⁴³	Nonrandomized	USA	Kaiser Permanente Walnut Creek	Integrated health system	+++	OC-Sensor	Routine + Reminder	n/a	X	X	X			82.7	n/a
Fedewa et al.⁴⁴	Nonrandomized	USA	Emory University School of Medicine	Integrated health system	+++	n/a	Routine + Reminder	n/a		X	X	X		n/a	n/a
Mehta et al.⁴⁵	Nonrandomized	USA	Division of Gastroenterology, Department of Medicine, Perelman School of Medicine	Integrated health system	+++	n/a	Routine + Enhanced Monitoring + Reminder	n/a	X		X		X	44.0	n/a
Luthgens et al.⁴⁶	Randomized	USA	Division of Gastroenterology, Zuckerberg San Francisco General Hospital	Community clinic	+	OC-Sensor	Enhanced Instructions + Reminder	Clinic	X	X	X			38.7	n/a
Singal et al.⁴⁷	Randomized	USA	Department of Internal Medicine, UT Southwestern Medical Center	Community clinic	+	OC-Auto	Enhanced Instructions + Reminder	n/a	X	X	X		X	28.0	n/a

Study eligibility and selection

We sought to evaluate studies with details on how patients were selected for mailed outreach CRC screening programs in community-based health care systems. The reviewers (AW, BL) appraised the pertinent studies to determine eligibility and studies were included if they: (1) used mailed FIT or immunochemical fecal occult blood test, (2) reported > 5000 patients (large CRC screening program). To reduce heterogeneity, large CRC screening programs were selected for the purposes of population screening automation as compared to the individualized selection process in smaller CRC screening programs. Included articles were grouped by the corresponding author’s affiliate health organization. The most recent article to date of each institute was selected for descriptive analysis. We included randomized controlled trials and nonrandomized controlled trials. Non-English language articles were translated through the publisher’s website or Google translator but none were included. We excluded studies using guaiac fecal occult blood test² (i.e. a different stool test using three samples with a lower compliance rate⁴⁸), out-of-scope review articles, population surveys, simulation model, and conference abstracts without accompanying full manuscripts.

Data abstraction

Our search strategy is shown in Supplemental Table 1. Titles and abstracts were evaluated for initial screening. Full text articles were assessed for eligibility and subsequent abstracted for study inclusion. At all stages, the reviewers (AW, BL) independently reviewed and abstracted data from the included studies into a Microsoft Excel Spreadsheet (version 2016; Microsoft, Redmond, WA, USA). Information was abstracted on article information, country, primary health organization of corresponding author, program type, number of study patients, FIT brand, intervention type, patient identification sources, patient exclusion criteria, FIT completion rate, and colonoscopy follow-up after positive FIT completion rate. Any disagreements in eligibility and abstraction were resolved through discussion (κ = 0.68, 83% of agreement, substantial agreement).

Data synthesis

Mailed FIT articles were summarized according to study design, program type (national or regional involvement, community clinic local involvement, integrated health system/integrated managed care consortium involvement), country, number of participants (+ = 5000–9999, ++ = 10,000–50,000, +++ = >50,001), type of FIT, outreach intervention type (routine screening, enhanced instructions, enhanced monitoring, enhanced education, added reminder communication), and source of patient selection. Program types were considered to improve study generalizability and utilization applicability. Standard mailed FIT kits included notification to participate, brief education pamphlet, FIT device, and manufacturer FIT instructions. Routine screening was defined as annual or biennial testing depending on the accepted practice standards in that country. Enhanced instruction was defined as tutorials, pictorials, low-literacy wordings. Enhanced monitoring was defined as additional navigators and tracking systems for patients. Enhanced education was defined as low-literacy wordings, and psychosocial and racial ethnic modifications. Added reminder communication was defined as the addition of mail, email, text message, or phone call reminders to patients to complete screening. Mailed FIT studies with additional interventional components did not lead to exclusion of the study.

Patient exclusion criteria were abstracted from each article. They were determined a priori (established by a preliminary search) and categorized into the following groups: comorbidities, personal or family history of CRC-related conditions, or uncategorized. Comorbidities included CRC-related symptoms (blood in stool, bowel obstructions), inflammatory bowel disease, institutionalization, and terminal diseases. Being up to date with routine CRC screening included colonoscopy in the prior 5–10 years, sigmoidoscopy in the prior 5 years, FIT in prior year, positive FIT, and colectomy. Personal or family history of related CRC conditions included familial adenomatous polyposis, hereditary nonpolyposis cancer, and other cancers.

Risk of bias was not assessed as the outcomes would not be affected by the study’s quality.

Key informant surveys and interviews

Key informant surveys and interviews were performed by emailing the corresponding authors of included articles (Supplemental Tables 5 and 6). The online email survey included questions on program type, location, patient identification source, patient inclusion and exclusion criteria, and technical selection codes (if any) (Supplemental Table 7). A standard e-mail template was followed, which invited corresponding authors to participate. Authors had two weeks to respond before a final reminder email was sent (Supplemental Table 8).

Analytical plan

A mixed methods approach was taken to gather study data. The review focused on summarizing study characteristics, patient identification and selection, FIT completion and CRC follow-up participation, and key informant surveys from articles with patient exclusions. Characteristics, the selection process, and outreach surveys were described as counts and proportions. Participation was described in ranges. Technical procedure codes (International Classification of Disease (ICD), Current Procedural Terminology (CPT), Healthcare Common Procedure Coding System (HCPCS), Logical Observation Identifiers Names and Codes (LOINC)) were summarized by patient exclusion categories. Due to the high risk of bias over differences in study characteristics, a meta-analysis was not performed. Our analysis approach was to focus on implementation strategies in mailed FIT outreach that accounted for individual patients, and contextualizing the risks (exclusion criteria) of the screening process. Any disagreements in synthesis and analysis were resolved through discussion and expressed as Cohen’s kappa (κ).

Compliance with ethical standards

All authors had access to the study data and reviewed and approved the final article. This study was exempt. The authors have no conflicts of interest to declare.

Results

Summary of literature search and study selection

After removal of duplicate records, the search identified 2081 articles, of which 434 full-text articles were evaluated (Figure 1). A total of 72 reports remained after stand-alone abstracts, commentaries or guideline articles, and duplicates were excluded. Articles that did not distribute FIT by mail, were not relevant, or were simulation models, systematic or meta-analysis reviews, or proposal articles were also excluded. To prevent duplication of results from the same CRC screening program, we included the most recent article from centers with multiple publications on the same cohort (Supplemental Table 3). After limiting articles to those with more than 5000 participants, 43 articles remained. Thirty articles contained documentation of patient exclusion criteria (Table 1) and 13 articles did not (Supplemental Table 2). Of the articles with no patient exclusion, 11 studies were from national and regional programs, and 8 studies used population registries as the source of patient outreach.

Figure 1.

Flow chart of study selection to evaluate implementation strategies that select patients for colorectal cancer screening program in community-based health care systems.

Table 2.

Technical codes identified and used to optimize patient selection for colorectal cancer screening.

Exclusion criteria categories	Current procedural terminology (CPT) (n = 5)	International Classification of Disease (ICD9) (n = 6)	Health care common procedure coding system (HCPCS) (n = 1)	Logical observation identifiers names and codes (LOINC) (n = 1)
Colonoscopy	44388-44394, 44397, 45355, 45378-45387, 45391, 45392	45.22-45.25, 45.42, 45.43	G0105, G0121
CT-Colonography	74261-74263
Sigmoidoscopy	45330-45335, 45337-45342, 45345	45.24, 45.42	G0104
Stool blood	82270, 82274	76.51, 578.xx, V76.51	G0107, G0328, G0394	2335-8, 12503-9, 12504-7, 14563-1, 14564-9, 14565-6, 27396-1, 27401-9, 27925-5, 27925-7, 29771-3, 50196-5, 56490-6, 56491-4, 57905-2, 58453-2
Barium enema	7,42,70,74,280		G0106, G0120, G0122
Iron deficiency anemia		280.9
Chronic diarrhea		787.91
Total colectomy	44150-44153, 44155-44156, 44210-44212	45.8
History of inflammatory bowel disease		555-555.2, 555.9, 556-556.6, 556.8, 556.9
History of colorectal polyps		211.3, 211.4, 230.3, 230.4, V12.72
History of cancer		153.0-154.8
History of GI cancer		159, 197.5, 197.8, 211.9, 230.3, 230.4, 230.7, 235.2, 239.0, V10.05

Characteristics of mailed FIT programs with patient exclusion

Of the 30 articles (22% missing data, “n/a”) that contained documentation describing patient exclusion (Table 1), 7 were randomized studies. Fourteen countries were represented and the majority of studies were from the United States (n = 8), France (n = 4), Spain (n = 4), and Italy (n = 3). Some countries despite having well-established CRC programs were not included if selection criteria was not defined (Supplemental Tables 2 and 3). Other excluded studies did not meet study inclusion criteria (Figure 1) or had no published reports.

In the subset of large CRC screening programs that utilized a mailed FIT approach with patient exclusions, 17 studies were at the national or regional level, 8 studies at the community clinic level, and 5 studies at the integrated health organization level. The number of patients in the screening program ranged in size: 5000 to 9999 (n = 9), 10,000 to 49,999 (n = 9), 50,000+ patients (n = 12). The cohort used a variety of FIT kits: OC-Sensor (n = 12), OC-Auto (n = 8), OC-Hemodial (n = 1), or not reported (n = 11).

Study outreach interventions were diverse. Integrated health organizations and community clinics were more likely to incorporate other interventions in addition to mailed FIT outreach (Table 1). Among community clinics (n = 8), mailed FIT interventions varied with each program using one or a combination of the following: no additional intervention (n = 4), reminder (n = 5), enhanced monitoring (n = 1), enhanced education (n = 1), enhanced instructions (n = 3). Among integrated health organizations (n = 5), interventions included one or a combination of the following: routine (n = 5), reminder (n = 4), enhanced monitoring (n = 2). Finally, among national or regional CRC programs (n = 17), interventions included: routine (n = 16), reminder (n = 5), enhanced monitoring (n = 1), enhanced education (n = 2).

Patient identification and selection in programs with patient exclusion

Community-based programs (n = 8) used various methods for patient outreach and selection (Table 1). Four studies removed patients up to date with CRC screening, and six studies utilized a personal cancer history, five studies incorporated patient comorbidities, and one study used family history of cancer as reasons to exclude individuals from receiving FIT mailing. Generally, smaller community-based programs (n = 4) relied on their own electronic medical care records (EMR) or individual or primary care provider/general practitioner (PCP/GP) selection (n = 2) as the source for patient identification, to which they applied subsequent exclusionary criteria.

Integrated health systems (n = 5) used similar methods for patient outreach and selection (Table 1). Three studies removed patients up to date with CRC screening, and five studies utilized a personal cancer history, three studies incorporated patient comorbidities, and one study used family history of cancer as reasons to exclude individuals from receiving FIT mailing. Integrated health organizations often had a large number of patients participating (>50,000, n = 4), and only one study reported relying on internally linked shared EMR as the source for patient identification across the consortium of health clinics in the area.

National or regional programs (n = 17) used similar methods for patient outreach and selection (Table 1). Twelve studies removed patients up to date with CRC screening, and 11 studies utilized a personal cancer history, 12 studies incorporated patient comorbidities, and 7 studies used family history of cancer as reasons to exclude individuals from receiving FIT mailing. The vast majority of these programs had a higher number of patients participating (>10,000, n = 14). While national or regional programs included three studies that utilized population registries and four studies that utilized local clinics for indiscriminant mass screening, patients were often sent informative leaflets (n = 4) asking them to “self opt-out” if they did not qualify. After inclusion, few programs (n = 2) verified a patient’s eligibility through EMR or surveys.

Participation in programs with patient exclusion

From the 30 studies included, broad ranges in FIT completion (n = 26) and subsequent (n = 11) colonoscopy follow-up were observed. National and regional programs were more likely to have higher median participation rates (Table 1) and reported FIT completion also varied. Completion of mailed FIT in community-based programs (n = 7) ranged from 31.0% to 59.6%, in integrated health systems (n = 3) from 21.2% to 82.7%, and in national or regional programs (n = 16) from 23.0% to 64.7%. In studies with reported colonoscopy follow-up after abnormal FIT, the results were: community-based programs (n = 5, 70.0–94.0%), integrated health systems (n = 1, 50.8%), and national or regional programs (n = 5, 65.7–97.0%).

Key informant surveys and interviews

Of the 28 studies (65% response rate) that responded to the survey and interview inquiry (Supplemental Table 4), responses were from individuals representing national (n = 11) and integrated health systems (n = 17). Corresponding authors identified patients for FIT outreach based on data obtained from the following sources: EMR (n = 13), population registries (n = 10), patient opt-in (n = 4), and PCP referral (n = 1). In total, six studies reported utilizing technical codes (all integrated health systems), seven studies required self-reporting from a questionnaire to participate (n = 3 national, n = 4 integrated health systems), and fifteen studies did not further elaborate on the selection process.

The common technical codes gathered from key informant outreach used to identify patients for outreach are outlined (and defined) in Table 2: colonoscopy (CPT 44388–44394, 44397, 45355, 45378–45387, 45391, 45392; ICD9 45.22–45.25, 45.42, 45.43; HCPCS G0105, G012), CT colonoscopy (CPT 74261–74263), sigmoidoscopy (CPT 45330–45335, 45337–45342, 45345; ICD9 45.24, 45.42; HCPCS G0104), stool blood (CPT 8,22,70,82,274; ICD9 76.51, 578.xx, V76.51; HCPCS G0107, G0328, G0394; LOINC 2335–8, 12503–9, 12504–7, 14563–1, 14564–9, 14565–6, 27396–1, 27401–9, 27925–5, 27925–7, 29771–3, 50196–5, 56490–6, 56491–4, 57905–2, 58453–2), barium enema (CPT 7,42,70,74,280; HCPCS G0106, G0120, G0122), iron deficiency anemia (ICD9 280.9), chronic diarrhea (ICD9 787.91), total colectomy (CPT 44150–44153, 44155–44156, 44210–44212; ICD9 45.8), history of inflammatory bowel disease (ICD9 211.3, 211.4, 230.3, 230.4, V12.72), history of colorectal polyps (ICD9 153.0–154.8), and history of gastrointestinal cancer (ICD9 159, 197.5, 197.8, 211.9, 230.3, 230.4, 230.7, 235.2, 239.0, V10.05). While two studies reported utilizing ICD10, codes were unspecified and not incorporated.

Discussion

While CRC screening rates have improved globally, they still remain suboptimal and the COVID-19 pandemic has now stalled in-person screening efforts. This review, describing the use of population registries and electronic records, offers an opportunity for health systems to transform from opportunistic screening to population-level screening, which has the potential to reduce CRC incidence and mortality. As health records become increasingly digitized, using algorithmic metrics to identify patients for CRC screening is an important first step to improving precision population health.^6,7 To our knowledge, our systematic review is the first to describe the methods by which screening programs identify and select patients for mailed FIT outreach programs. We show that while national or regional CRC screening programs typically rely on population registries for patient self-reported exclusion or direct GP/PCP recruitment, community clinics and integrated health organizations use internal electronic health records to select patients for screening. In addition, there are many large CRC screening programs around the world that use cancer history and comorbidities as exclusionary criteria.

Organized screening programs in large health care systems have been shown to increase participation, improve patient handling of FIT, reduce disparities, reduce potential harms of screening, and reduce the overall care costs.^49–51 And multiple studies have demonstrated the effectiveness and acceptable cost of mailed FIT outreach.^8–16,49 In the United States, population health entities within integrated health systems have arisen due to the adoption of electronic health records. To date, they often serve to report on the quality of care in order to obtain payment incentives. However, through the data infrastructure, population health entities should also transition to provide clinical services that improve the health of populations. In this review, we also identified multiple publications from Kaiser Permanente in different regions of the United States; they have previously described a centrally organized CRC screening model that includes mailed FIT kits.^11,12 As digitization of health and centrally managed mailed FIT programs become more widespread, these population health entities can enhance overall health care maintenance and cancer prevention. Therefore, a concerted effort should be made to improve tailored prevention with the goal of refining patient selection criteria for a more personalized and cost-effective outcome.⁵⁰ Specifically, to ensure trust between health systems, providers, and patients, organized outreach should offer screening to patients whose provider would have also intended to screen. In this review, while we identified 30 articles and ascertained each of their patient eligibilities with variable cohort definitions, the implementation strategies used for mailed FIT outreach were lacking. For example, while we suspect most studies used algorithmic code to identify patients for CRC screening, only one study specified ICD/common procedural codes.

While implemented CRC screening practices have historically limited patients by age, risk, and lack of symptoms,² this study shows that health organizations often implement different methods for identifying patient comorbidities or history of cancer-related conditions, leading to inconsistent CRC screening participation.⁵¹ Moreover, the implementation of screening is markedly different across regions and countries. While not covered in this review, health care systems can proactively incorporate data elements used for Healthcare Effectiveness Data and Information Set (HEDIS) performance measures for CRC screening to develop population registries for targeted screening. As an example, the most recent HEDIS measure and technical resource provides guidance on excluding patients from the CRC report when there is use of palliative care or the medication donepezil for dementia. This review summarizes the patient selection criteria and the technical codes that exist in different health care settings, to inform health systems considering implementing mailed FIT outreach.

There are several limitations to this study. First, few studies report patient selection criteria or systems used to identify patients for outreach. Different health organizations may have had internal practices; however, the specified metrics of patient identification and acquisition used in varying clinic practices were not articulated in the manuscript or through contact with the authors. Second, there is a potential for section bias as we only described a subgroup of studies that utilized mailed FIT and published their data. We are aware that multiple national programs exist but published data, along with the specified processes around selection of patients for screening, were not publicly available. We may have also missed other patient selection processes because we excluded smaller studies (<5000 participants) from our review. From a systems implementation perspective, we excluded small studies because these were more likely to involve patient selection processes that were not economical (e.g. consent of patients, chart review, permission from provider) for population health screening automation. Finally, we cannot directly compare or perform a meta-analysis on screening outcomes with respect to selection criteria due to the heterogeneity in targeting populations for screening. Difference in screening outcomes may be of interest but cannot be meaningfully compared given the differences between the individual CRC screening programs.

In conclusion, our systematic review with key informant interviews describes the patient selection criteria and implementation strategies of 30 studies. We found that large CRC screening programs may use heterogenous methods for excluding patients for FIT outreach. This systematic review sought to provide health systems with the technical tools to support efforts to automate patient selection for CRC screening outreach. These efforts are particularly timely given the COVID-19 pandemic, which has increased concern for in-person visits and has accelerated the adoption of telehealth and organized outreach services. Optimizing the patient identification process and selection criteria can strengthen preventive care services, improve patient outcomes, and reduce cost.

Supplemental Material

sj-pdf-1-msc-10.1177_0969141321997482 - Supplemental material for Selection of patients for large mailed fecal immunochemical test colorectal cancer screening outreach programs: A systematic review

Supplemental material, sj-pdf-1-msc-10.1177_0969141321997482 for Selection of patients for large mailed fecal immunochemical test colorectal cancer screening outreach programs: A systematic review by Andrew Wang, Briton Lee, Shreya Patel, Evans Whitaker, Rachel B Issaka and Ma Somsouk in Journal of Medical Screening

Footnotes

Authors’ contribution

Andrew Wang – drafting of the article; acquisition of data; interview outreach; analysis and interpretation of data; and critical revision of the article. Briton Lee – acquisition of data. Shreya Patel – acquisition of data; interview outreach; analysis and interpretation of data; and critical revision of the article. Evans Whitaker – technical or material support; study concept and design (search terms). Rachel B Issaka – study concept and design; critical revision of the article. Ma Somsouk – principal investigator; study concept and design; interview outreach; analysis and interpretation of data; critical revision of the article; and study supervisor.

Acknowledgments

The authors are grateful to Robert Hiatt, MD, PhD and David Glidden, PhD (Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA) for their insightful feedback and continued support of the study.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the San Francisco Cancer (SF CAN) Initiative, a collaborative community effort initiated by the UCSF HDFCCC to reduce the cancer burden across the city and beyond []. Dr Issaka was supported by the National Institutes of Health/National Cancer Institute award number K08 CA241296.

ORCID iD

Andrew Wang

Supplemental material

Supplemental material for this article is available online.

References

Siegel

Miller

Jemal

Cancer statistics, 2017. CA Cancer J Clin 2017; 67: 7–30.

Bibbins-Domingo

Grossman

Curry

, et al. Screening for colorectal cancer: US preventive services task force recommendation statement. JAMA 2016; 315: 2564–2575.

DeGroff

Increasing colorectal cancer screening in health care systems using evidence-based interventions. Prev Chronic Dis 2018; 15: E100.

Dubé

Tackling colorectal cancer as a public health issue: what can the gastroenterologist do?

Can J Gastroenterol 2012; 26: 417–418.

Bruel

A d

Jones

Yang

, et al. People’s willingness to accept overdetection in cancer screening: population survey. BMJ 2015; 350: h980–h980.

Atasoy

Greenwood

McCullough

JS.

The digitization of patient care: a review of the effects of electronic health records on health care quality and utilization. Annu Rev Public Health 2019; 40: 487–500.

Zapka

Puleo

Vickers-Lahti

, et al. Healthcare system factors and colorectal cancer screening. Am J Prev Med 2002; 23: 28–35.

Issaka

Avila

Whitaker

, et al. Population health interventions to improve colorectal cancer screening by fecal immunochemical tests: a systematic review. Prev Med 2019; 118: 113–121.

Rachocki

Laleau

Garcia

, et al. Mailed FIT to improve colorectal cancer screening in an integrated safety-net system. Gastroenterology 2017; 152: S75.

10.

Gupta

Halm

Rockey

, et al. Comparative effectiveness of fecal immunochemical test outreach, colonoscopy outreach, and usual care for boosting colorectal cancer screening among the underserved. JAMA Intern Med 2013; 173: 1725–1732.

11.

Levin

Corley

Jensen

, et al. Effects of organized colorectal cancer screening on cancer incidence and mortality in a large Community-Based population. Gastroenterology 2018; 155: 1383–1391.e5.

12.

Levin

Jamieson

Burley

, et al. Organized colorectal cancer screening in integrated health care systems. Epidemiol Rev 2011; 33: 101–110.

13.

Guy

Richardson

Pignone

, et al. Costs and benefits of an organized fecal immunochemical test-based colorectal cancer screening program in the United States. Cancer 2014; 120: 2308–2315.

14.

Dougherty

Brenner

Crockett

, et al. Evaluation of interventions intended to increase colorectal cancer screening rates in the United States: a systematic review and meta-analysis. JAMA Intern Med 2018; 178: 1645–1658.

15.

Davis

Freeman

Shannon

, et al. A systematic review of clinic and community intervention to increase fecal testing for colorectal cancer in rural and low-income populations in the United States – how, what and when? BMC Cancer 2018; 18.

16.

Coronado

Petrik

Vollmer

, et al. Effectiveness of a mailed colorectal cancer screening outreach program in community health clinics: the STOP CRC cluster randomized clinical trial. JAMA Intern Med 2018; 178: 1174–1181.

17.

Klabunde

Meissner

Wooten

, et al. Comparing colorectal cancer screening and immunization status in older Americans. Am J Prev Med 2007; 33: 1–8.

18.

DuBard

Schmid

Yow

, et al. Recommendation for and receipt of cancer screenings among medicaid recipients 50 years and older. Arch Intern Med 2008; 168: 2014–2021.

19.

Duncan

Zajac

Flight

, et al. Comparison of mailed invitation strategies to improve fecal occult blood test participation in men: protocol for a randomized controlled trial. Trials 2013; 14: 239.

20.

Van Roosbroeck

Hoeck

Van Hal

Population-based screening for colorectal cancer using an immunochemical faecal occult blood test: a comparison of two invitation strategies. Cancer Epidemiol 2012; 36: e317–e324.

21.

Telford

Gentile

Gondara

, et al. Performance of a quantitative fecal immunochemical test in a colorectal cancer screening pilot program: a prospective cohort study. CMAJ Open 2016; 4: E668–E673.

22.

Larsen

Mikkelsen

Rasmussen

, et al. Sociodemographic characteristics of nonparticipants in the Danish colorectal cancer screening program: a nationwide cross-sectional study. Clin Epidemiol 2017; 9: 345–354.

23.

Sportes

Catajar

Charles

, et al. Invitation letter with a standardized form is a reliable tool to exclude increased risk patients from organized fecal immunological testing-based colorectal cancer screening program. Dig Liver Dis 2018; 50: 1339–1342.

24.

Pellat

Deyra

Coriat

, et al. Results of the national organised colorectal cancer screening program with FIT in Paris. Sci Rep 2018; 8: 4162.

25.

Koïvogui

Mab

Benamouzig

Detection of colorectal neoplasia in a cohort before and after the change of fecal occult blood test in a French colorectal cancer screening program. Am J Gastroenterol 2018; 113: 1891–1899.

26.

Rat

Pogu

Le Donné

, et al. Effect of physician notification regarding nonadherence to colorectal cancer screening on patient participation in fecal immunochemical test cancer screening. JAMA 2017; 318: 816–824.

27.

McNamara

Leen

Seng-Lee

, et al. Sustained participation, colonoscopy uptake and adenoma detection rates over two rounds of the Tallaght–Trinity college colorectal cancer screening programme with the faecal immunological test. Eur J Gastroenterol Hepatol 2014; 26: 1415–1421.

28.

Clarke

McNamara

Kearney

, et al. The role of area-level deprivation and gender in participation in population-based faecal immunochemical test (FIT) colorectal cancer screening. Prev Med 2016; 93: 198–203.

29.

Giorgi Rossi

Vicentini

Sacchettini

, et al. Impact of screening program on incidence of colorectal cancer: a cohort study in Italy. Am J Gastroenterol 2015; 110: 1359–1366.

30.

Grazzini

Ciatto

Cislaghi

, et al. Cost evaluation in a colorectal cancer screening programme by faecal occult blood test in the District of Florence. J Med Screen 2008; 15: 175–181.

31.

Senore

Ederle

DePretis

, et al. Invitation strategies for colorectal cancer screening programmes: the impact of an advance notification letter. Prev Med 2015; 73: 106–111.

32.

Santare

Kojalo

Huttunen

, et al. Improving uptake of screening for colorectal cancer: a study on invitation strategies and different test kit use. Eur J Gastroenterol Hepatol 2015; 27: 536–543.

33.

van der Vlugt

Grobbee

Bossuyt

, et al. Adherence to colorectal cancer screening: four rounds of faecal immunochemical test-based screening. Br J Cancer 2017; 116: 44–49.

34.

Knudsen

Berstad

Hjartåker

, et al. Lifestyle predictors for non-participation and outcome in the second round of faecal immunochemical test in colorectal cancer screening. Br J Cancer 2017; 117: 461–469.

35.

Vanaclocha-Espi

Ibáñez

Molina-Barceló

, CRIBEA Groupet al. Factors influencing participation in colorectal cancer screening programs in Spain. Prev Med 2017; 105: 190–196.

36.

Guiriguet

Pera

Castells

, et al. Impact of comorbid conditions on participation in an organised colorectal cancer screening programme: a cross-sectional study. BMC Cancer 2017; 17.

37.

Binefa

García

Milà

, et al. Colonoscopy quality assessment in a mass population screening programme based on faecal occult blood test. Rev Esp Enferm Dig 2013; 105: 400–408.

38.

Quintero

Castells

Bujanda

, et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med 2012; 366: 697–706.

39.

Chen

Tsai

Wen

CP.

Extending colorectal cancer screening to persons aged 40 to 49 years with immunochemical fecal occult blood test: a prospective cohort study of 513,283 individuals. J Clin Gastroenterol 2016; 50: 761–768.

40.

Vleugels

JLA

Dijkgraaf

MGW

Hazewinkel

, et al. Effects of training and feedback on accuracy of predicting rectosigmoid neoplastic lesions and selection of surveillance intervals by endoscopists performing optical diagnosis of diminutive polyps. Gastroenterology 2018; 154: 1682–1693.e1.

41.

Kemper

Glaze

Eastman

, et al. Effectiveness and cost of multilayered colorectal cancer screening promotion interventions at federally qualified health centers in Washington State. Cancer 2018; 124: 4121–4129.

42.

Skootsky

Grossman

, et al. A multi-level fit-based quality improvement initiative to improve colorectal cancer screening in a managed care population. Clin Transl Gastroenterol 2018; 9.

43.

Corley

Jensen

Quinn

, et al. Association between time to colonoscopy after a positive fecal test and risk of colorectal cancer stage at diagnosis. JAMA 2017; 317: 1631–1641.

44.

Fedewa

Corley

Jensen

, et al. Colorectal cancer screening initiation after age 50 years in an organized program. Am J Prev Med 2017; 53: 335–344.

45.

Mehta

Jensen

Quinn

, et al. Race/ethnicity and adoption of a population health management approach to colorectal cancer screening in a community-based healthcare system. J Gen Intern Med 2016; 31: 1323–1330.

46.

Lüthgens

Albert

Brenner

, et al. Tests for occult blood underline the necessity of standardization and quality assurance. Z Gastroenterol 2016; 54: 299–303.

47.

Singal

Gupta

Skinner

, et al. Effect of colonoscopy outreach vs fecal immunochemical test outreach on colorectal cancer screening completion: a randomized clinical trial. JAMA 2017; 318: 806–815.

48.

Hoffman

Steel

Yee

, et al. Colorectal cancer screening adherence is higher with fecal immunochemical tests than guaiac-based fecal occult blood tests: a randomized, controlled trial. Prev Med 2010; 50: 297–299.

49.

Gupta

Coronado

Argenbright

, et al. Mailed fecal immunochemical test outreach for colorectal cancer screening: summary of a centers for disease control and prevention. CA Cancer J Clin 2020; 70: 283–298.

50.

Glasgow

Kwan

Matlock

DD.

Realizing the full potential of precision health: the need to include patient-reported health behavior, mental health, social determinants, and patient preferences data. J Clin Transl Sci 2018; 2: 183–185.

51.

Mack

Stuart

Temple

WJ.

Survey of colorectal cancer screening practices in a large Canadian urban Centre. Can J Surg 2004; 47: 189–194.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.43 MB